

國立成功大學  
110學年度碩士班招生考試試題

編 號：284

系 所：臨床藥學與藥物科技研究所

科 目：藥劑學

日 期：0203

節 次：第 1 節

備 註：不可使用計算機

編號：284

國立成功大學 110 學年度碩士班招生考試試題

系 所：臨床藥學與藥物科技研究所

考試科目：藥劑學

考試日期：0203，節次：1

第 1 頁，共 2 頁

※ 考生請注意：本試題不可使用計算機。請於答案卷(卡)作答，於本試題紙上作答者，不予計分。

1. Explain the following terminology/equation and their applications in pharmaceuticals. (16%)
  - (1)  $Q_{10}$
  - (2) Triangular phase diagram
  - (3) Higuchi equation
  - (4) Young's equation
  
2. Please elaborate, according to Good Manufacturing Practices, how to minimize the risk of microbial, particulate and pyrogen contamination in the manufacturing process of sterile products? (15%)
  
3. List three commonly-used stabilizing agents in the formulations of biological products, and explain their effect. (9%)
  
4. Describe the factors that influence the physical stability of suspensions, and how to improve it by formulation. (10%)
  
5. What is the Biopharmaceutical Classification System (BCS)? How do you determine the BCS classification of a drug? (14%)
  
6. The volume of distribution of a lipophilic drug X is about 300 L. For each of the following statements, indicate whether it is consistent with this observation or not. If not or ambiguous, provide an explanation for it. (12%)
  - (1) Plasma protein binding is more pronounced than tissue binding.
  - (2) Tissue binding is more pronounced than plasma protein binding.
  - (3) The distribution of drug X is more likely to be permeability-rate limited.
  - (4) Drug X can not be an acid or base as it is able to cross membranes.
  - (5) The clearance of drug X has to be high.
  - (6) The half-life of drug X has to be long.

7. The following pharmacokinetic parameters were reported for a drug Y:  
 Oral bioavailability (F)- 0.56;  
 Fraction excreted unchanged in urine (fe)- 0.2;  
 Unbound fraction in plasma (fu)- 0.3;  
 Volume of distribution (Vd)- 0.8 L/Kg;  
 Elimination half-life ( $t_{1/2}$ )- 1.39 hr.  
 A patient (40 years old, 70 kg, GFR 100 mL/min) was prescribed 300 mg oral dose of drug Y every 6 hr for a week.

- (1) Calculate the total body clearance (CL) of the drug in this patient. (4%)
- (2) Calculate the renal clearance (CL<sub>r</sub>). (4%)
- (3) What is the probable mechanism for renal elimination of this drug? (4%)
- (4) Estimate the average steady-state plasma drug concentration for this patient. (4%)

8. Select the plots that agree with linear pharmacokinetics. (8%)  
 AUC: Area under concentration-time curve; CL: Total body clearance; K: Elimination rate constant; Vd: Volume of distribution.

The plots are arranged in a 4x3 grid:

- Row 1: (1) CL vs Dose (horizontal line), (2) CL vs Dose (linear line through origin), (3) CL vs Dose (curved line increasing with dose)
- Row 2: (4) Vd vs Dose (curved line increasing with dose), (5) Vd vs Dose (horizontal line), (6) Vd vs Dose (linear line through origin)
- Row 3: (7) AUC vs Dose (linear line through origin), (8) AUC vs Dose (curved line increasing with dose), (9) AUC vs Dose (horizontal line)
- Row 4: (10) K vs Dose (curved line increasing with dose), (11) K vs Dose (linear line through origin), (12) K vs Dose (curved line increasing with dose)